Review: taking Venlafaxine hydrochloride and Amphetamine salt combo together


Summary

Drug interactions are reported among people who take Venlafaxine hydrochloride and Amphetamine salt combo together. This review analyzes the effectiveness and drug interactions between Venlafaxine hydrochloride and Amphetamine salt combo. It is created by eHealthMe based on reports of 1,317 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Venlafaxine Hydrochloride

Venlafaxine hydrochloride has active ingredients of venlafaxine hydrochloride. It is often used in depression. (latest outcomes from Venlafaxine hydrochloride 5,424 users)

Amphetamine Salt Combo

Amphetamine salt combo has active ingredients of amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Amphetamine salt combo 421 users)

On Sep, 21, 2016

1,317 people who take Venlafaxine Hydrochloride, Amphetamine Salt Combo are studied.


Number of reports submitted per year:

Venlafaxine hydrochloride and Amphetamine salt combo drug interactions.

Drug effectiveness over time:

Venlafaxine Hydrochloride:
  • < 1 month: 6.0% - (1 of 16 people)
  • 1 - 6 months: 20.0% - (4 of 20 people)
  • 6 - 12 months: 16.0% - (6 of 36 people)
  • 1 - 2 years: 41.0% - (14 of 34 people)
  • 2 - 5 years: 33.0% - (18 of 53 people)
  • 5 - 10 years: 38.0% - (12 of 31 people)
  • 10+ years: 41.0% - (7 of 17 people)
  • not specified: 50.0% - (1 of 2 people)
Amphetamine Salt Combo:
  • < 1 month: 33.0% - (4 of 12 people)
  • 1 - 6 months: 48.0% - (21 of 43 people)
  • 6 - 12 months: 51.0% - (15 of 29 people)
  • 1 - 2 years: 68.0% - (35 of 51 people)
  • 2 - 5 years: 57.0% - (24 of 42 people)
  • 5 - 10 years: 48.0% - (12 of 25 people)
  • 10+ years: 80.0% - (8 of 10 people)
  • not specified: 33.0% - (1 of 3 people)

Drug effectiveness by gender:

Venlafaxine Hydrochloride:
  • female: 31.0% - (51 of 160 people)
  • male: 24.0% - (12 of 49 people)
Amphetamine Salt Combo:
  • female: 54.0% - (90 of 164 people)
  • male: 58.0% - (30 of 51 people)

Drug effectiveness by age:

Venlafaxine Hydrochloride:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 20.0% - (1 of 5 people)
  • 20-29: 36.0% - (21 of 57 people)
  • 30-39: 20.0% - (11 of 54 people)
  • 40-49: 35.0% - (19 of 54 people)
  • 50-59: 31.0% - (10 of 32 people)
  • 60+: 14.0% - (1 of 7 people)
Amphetamine Salt Combo:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 28.0% - (2 of 7 people)
  • 20-29: 63.0% - (36 of 57 people)
  • 30-39: 51.0% - (30 of 58 people)
  • 40-49: 53.0% - (29 of 54 people)
  • 50-59: 56.0% - (18 of 32 people)
  • 60+: 71.0% - (5 of 7 people)

Most common drug interactions over time *:

< 1 month:
  • feeling abnormal
  • vomiting
  • depression
  • pain
  • intentional overdose
  • suicide attempt
  • dizziness
  • fatigue
  • insomnia
  • nausea
1 - 6 months:
  • death
  • bronchiolitis
  • cerebral dysgenesis
  • cerebral palsy
  • congenital anomaly
  • congenital cytomegalovirus infection
  • craniosynostosis
  • developmental delay
  • developmental hip dysplasia
  • eye disorder
6 - 12 months:
  • anxiety
  • depression
  • memory impairment
  • arthralgia
  • back pain
  • disturbance in attention
  • myalgia
  • breast cancer
  • breast cancer in situ
  • breast cyst
1 - 2 years:
  • anxiety
  • fatigue
  • sweating - excessive
  • mood swings
  • headache
  • obesity
  • adrenal glands
  • amenorrhoea
  • anorgasmia
  • bipolar disorder
2 - 5 years:
  • fatigue
  • sweating - excessive
  • weight gain
  • anxiety
  • pain
  • constipation
  • nausea
  • depression
  • feeling jittery
  • hair growth abnormal
5 - 10 years:
  • depression
  • exhaustion, fatigue, lethargy, tiredness, weariness
  • headache
  • anxiety
  • chest pain
  • memory impairment
  • weight gain
  • dyspnoea
  • itching
  • migraine
10+ years:
  • erectile dysfunction
  • anxiety
  • constipation
  • depression
  • dry mouth
  • dyshidrotic eczema
  • dysphoria
  • exhaustion, fatigue, lethargy, tiredness, weariness
  • feeling abnormal
  • headache
not specified:
  • fatigue
  • nausea
  • anxiety
  • depression
  • headache
  • pain
  • feeling abnormal
  • insomnia
  • somnolence
  • drug ineffective

Most common drug interactions by gender *:

female:
  • fatigue
  • anxiety
  • nausea
  • depression
  • feeling abnormal
  • pain
  • insomnia
  • headache
  • drug ineffective
  • chest pain
male:
  • headache
  • somnolence
  • depression
  • anxiety
  • fatigue
  • nausea
  • bite
  • pain
  • thirst
  • psychomotor hyperactivity

Most common drug interactions by age *:

2-9:
  • aggression
  • agitation
  • bipolar disorder
  • bite
  • convulsion
  • depression
  • homicidal ideation
  • intentional self-injury
  • screaming
  • staring
10-19:
  • psychomotor hyperactivity
  • thirst
  • depression
  • anxiety
  • multi-organ failure
  • pulmonary embolism
  • bite
  • cardiopulmonary failure
  • compulsions
  • hyperglycaemia
20-29:
  • anxiety
  • depression
  • nausea
  • drug withdrawal syndrome
  • feeling abnormal
  • fatigue
  • pain
  • drug ineffective
  • injury
  • abdominal pain upper
30-39:
  • anxiety
  • headache
  • nausea
  • feeling abnormal
  • fatigue
  • vomiting
  • dizziness
  • depression
  • insomnia
  • somnolence
40-49:
  • fatigue
  • cardiomegaly
  • respiratory distress
  • chest discomfort
  • insomnia
  • anxiety
  • pyrexia
  • depression
  • chest pain
  • pain
50-59:
  • nausea
  • depression
  • anxiety
  • pain
  • fall
  • fatigue
  • gait disturbance
  • back pain
  • sinusitis
  • chest pain
60+:
  • fatigue
  • headache
  • nausea
  • malaise
  • oedema peripheral
  • pain
  • vomiting
  • weight increased
  • maternal exposure during pregnancy
  • rash

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Venlafaxine hydrochloride and Amphetamine salt combo?

Can you answer these questions?

More questions for: Venlafaxine hydrochloride, Amphetamine salt combo

You may be interested in these reviews

More reviews for: Venlafaxine hydrochloride, Amphetamine salt combo

On eHealthMe, Venlafaxine hydrochloride (venlafaxine hydrochloride) is often used to treat depression. Amphetamine salt combo (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate) is often used to treat attention deficit hyperactivity disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.